China’s Country Garden looks to sell £450 million London development

Published Wed, Jan 31, 2024 · 07:20 PM

CHINESE property developer Country Garden has put its £450 million (S$764 million) residential development in East London up for sale as it presses ahead with asset disposals at home and overseas after defaulting on its offshore debt.

Property agent Knight Frank said it had been appointed by Risland UK – a subsidiary of Country Garden – to market the 1,000-home Calico Wharf development, where construction has yet to start, in the Poplar area of the city.

Country Garden, the largest private property developer in China, is among a string of developers reeling from a Chinese property crunch that began in mid-2021 after authorities sought to rein in excessive debt levels.

The firm is working on an offshore debt restructuring after it defaulted on US$11 billion worth of offshore bonds in October. It has also extended repayments for its onshore notes.

The market is watching its restructuring progress closely as peer China Evergrande Group, the world’s most indebted property developer, was ordered to liquidate by a Hong Kong court this week after its restructuring talks with creditors failed.

The UK project has planning approval for several buildings, including a tower of up to 23 storeys, and would include commercial space as well as homes, Knight Frank said in a statement.

A NEWSLETTER FOR YOU
Tuesday, 12 pm
Property Insights

Get an exclusive analysis of real estate and property news in Singapore and beyond.

Country Garden has also put properties in the Chinese city of Guangzhou up for sale with the aim of raising 3.8 billion yuan (S$712 million), and agreed to sell its stake in its last Australian project. REUTERS

KEYWORDS IN THIS ARTICLE

READ MORE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Property

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here